肿瘤坏死因子抑制剂在轴性脊柱关节炎中的生存率与应答预测因素:来自英国队列的发现
该回顾性研究纳入英国两个专科中心651例轴性脊柱关节炎患者,分析初始TNFi(肿瘤坏死因子抑制剂)的长期生存率、换药或停药原因及应答预测因素。结果显示初始与第二种TNFi中位药物生存期分别为10.2年和5.5年(P<0.05),药物选择不影响生存率,HLA-B27预测BASDAI50应答及长期药物生存。
要点
- 初始与第二种TNFi中位药物生存期分别为10.2年(95%CI 8.8–11.6)和5.5年(95%CI 2.7–8.3),P<0.05。
- TNFi选择不影响药物生存率,HLA-B27预测BASDAI50应答和长期药物生存(P<0.05)。
- 非吸烟和低基线BASDAI预测低疾病活动度(P<0.05)。
核心结论
- 在真实世界环境中观察到轴性脊柱关节炎患者良好的TNFi生存率,第一种TNFi最佳且不受药物选择影响。
研究设计与样本
- 回顾性分析英国两个专科中心就诊的651例经医生确诊并符合TNFi准入标准的轴性脊柱关节炎患者,常规记录数据被回顾性审查,初始TNFi记为索引药物。
主要发现
- 651例患者中94%为强直性脊柱炎,索引TNFi为阿达木单抗(n=332)、依那西普(n=205)、英夫利西单抗(n=51)、戈利木单抗(n=40)和培塞利珠单抗(n=23)。
- 从症状发作到诊断的平均(标准差)时间为8.6(8.7)年,从诊断到启用TNFi的平均(标准差)时间为12.6(11.5)年。
- 224例(34.4%)停用索引TNFi,其中105/224例换用第二种TNFi。
- 索引TNFi和第二种TNFi的中位药物生存期分别为10.2年(95%CI 8.8–11.6年)和5.5年(95%CI 2.7–8.3年),P<0.05。
- HLA-B27预测6个月内BASDAI50应答和/或BASDAI降低≥2分以及长期药物生存(P<0.05);非吸烟和低基线BASDAI预测低疾病活动度(P<0.05)。
关键数值与推荐
- 索引TNFi中位药物生存期10.2年(95%CI 8.8–11.6年)vs 第二种TNFi 5.5年(95%CI 2.7–8.3年),P<0.05。
- 224/651例(34.4%)停用索引TNFi,105/224例换用第二种TNFi。
- HLA-B27预测BASDAI50和/或BASDAI降低≥2分(6个月内)及长期药物生存(P<0.05)。
- 非吸烟和低基线BASDAI预测低疾病活动度(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse long-term survival and efficacy of TNFi, reasons for switching or discontinuing, baseline predictors of response and remission in axial spondyloarthritis (axSpA) patients in a UK cohort. METHODS: All patients with a physician-verified diagnosis of axSpA attending two specialist centres who fulfilled the eligibility criteria for TNFi were included. Routinely recorded patient data were reviewed retrospectively. Initial TNFi was recorded as the index drug. RESULTS: Six hundred and fifty-one patients (94% AS) were included; adalimumab (n = 332), etanercept (n = 205), infliximab (n = 51), golimumab (n = 40) and certolizumab pegol (n = 23) were index TNFi. The mean (s.d.) duration from symptom onset to time of diagnosis was 8.6 (8.7) years and mean (s.d.) duration from diagnosis to TNFi initiation was 12.6 (11.5) years. A total of 224 (34.4%) stopped index TNFi, and 105/224 switched to a second TNFi. Median drug survival for index and second TNFi were 10.2 years (95% CI: 8.8, 11.6 years) and 5.5 years (95% CI: 2.7, 8.3 years), respectively (P < 0.05). Survival rates were not influenced by choice of TNFi. HLA-B27 predicted BASDAI50 and/or two or more point reduction within 6 months and long-term drug survival (P < 0.05). Low disease activity was predicted by non-smoking and low baseline BASDAI (P < 0.05). CONCLUSION: We have observed good TNFi survival rates in axSpA patients treated in a real-life setting. This is best for first TNFi and not influenced by drug choice.
引用
- Yahya F, Gaffney K, Hamilton L, et al. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort. Rheumatology (Oxford). 2018. PMID: 29272541. doi:10.1093/rheumatology/kex457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。